- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2006 (2006), Article ID 24038, 5 pages
Heme Deficiency in Alzheimer's Disease: A Possible Connection to Porphyria
1Research Service (151), VA Medical ' Regional Office
Center, White River Junction, 05009, VT, USA
2Department of Medicine (Neurology), Dartmouth Medical School, Hanover 03755, NH, USA
3Institute of Pathology, Case Western Reserve University, Cleveland 44106, OH, USA
Received 1 December 2005; Revised 30 March 2006; Accepted 5 April 2006
Copyright © 2006 Barney E. Dwyer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- M A Smith, “Alzheimer disease,” International Review of Neurobiology, vol. 42, pp. 1–54, 1998.
- S W Scheff and D A Price, “Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies,” Neurobiology of Aging, vol. 24, no. 8, pp. 1029–1046, 2003.
- L S Schneider and K S Dagerman, “Psychosis of Alzheimer's disease: clinical characteristics and history,” Journal of Psychiatric Research, vol. 38, no. 1, pp. 105–111, 2004.
- B E Dwyer, A K Raina, G Perry, and M A Smith, “Homocysteine and Alzheimer's disease: a modifiable risk?,” Free Radical Biology and Medicine, vol. 36, no. 11, pp. 1471–1475, 2004.
- B E Dwyer, A Takeda, X Zhu, G Perry, and M A Smith, “Ferric cycle activity and Alzheimer disease,” Current Neurovascular Research, vol. 2, no. 3, pp. 261–267, 2005.
- H Atamna and W H II Frey, “A role for heme in Alzheimer's disease: heme binds amyloid and has altered metabolism,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 30, pp. 11153–11158, 2004.
- G H Elder, R J Hift, and P N Meissner, “The acute porphyrias,” The Lancet, vol. 349, no. 9065, pp. 1613–1617, 1997.
- U A Meyer, M M Schuurmans, and R LP Lindberg, “Acute porphyrias: pathogenesis of neurological manifestations,” Seminars in Liver Disease, vol. 18, no. 1, pp. 43–52, 1998.
- H L Bonkovsky and G F Barnard, “The porphyrias,” Current Treatment Options in Gastroenterology, vol. 3, no. 6, pp. 487–500, 2000.
- P N Meissner, R J Hift, and R E Kirsch, “The porphyrias,” in The Liver: Biology and Pathobiology, I M Arias, J L Boyer, F V Chisari, N Fausto, D Schacter, and D A Shafritz, Eds., pp. 311–329, Lippincott Williams and Wilkins, Philadelphia, Pa, 4th edition, 2001.
- J W Albers and J K Fink, “Porphyric neuropathy,” Muscle and Nerve, vol. 30, no. 4, pp. 410–422, 2004.
- K E Anderson, J R Bloomer, H L Bonkovsky, et al., “Recommendations for the diagnosis and treatment of the acute porphyrias,” Annals of Internal Medicine, vol. 142, no. 6, pp. 439–450, 2005.
- M N Badminton and G H Elder, “Molecular mechanisms of dominant expression in porphyria,” Journal of Inherited Metabolic Disease, vol. 28, no. 3, pp. 277–286, 2005.
- C Handschin, J Lin, J Rhee, et al., “Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1,” Cell, vol. 122, no. 4, pp. 505–515, 2005.
- D Li, “PGC-1: looking behind the sweet treat for porphyria,” Cell, vol. 122, no. 4, pp. 487–489, 2005.
- R LP Lindberg, R Martini, M Baumgartner, et al., “Motor neuropathy in porphobilinogen deaminase-deficient mice imitates the peripheral neuropathy of human acute porphyria,” Journal of Clinical Investigation, vol. 103, no. 8, pp. 1127–1134, 1999.
- R LP Lindberg, C Porcher, B Grandchamp, et al., “Porphobilinogen deaminase deficiency in mice causes a neuropathy resembling that of human hepatic porphyria,” Nature Genetics, vol. 12, no. 2, pp. 195–199, 1996.
- A Johansson, C Möller, J Fogh, and P Harper, “Biochemical characterization of porphobilinogen deaminase-deficient mice during phenobarbital induction of heme synthesis and the effect of enzyme replacement,” Molecular Medicine, vol. 9, no. 9–12, pp. 193–199, 2003.
- P A Wyss, S Boynton, J Chu, and K S Roth, “Tissue distribution of succinylacetone in the rat in vivo: a possible basis for neurotoxicity in hereditary infantile tyrosinemia,” Biochimica et Biophysica Acta, vol. 1182, no. 3, pp. 323–328, 1993.
- Z F Soonawalla, T Orug, M N Badminton, et al., “Liver transplantation as a cure for acute intermittent porphyria,” The Lancet, vol. 363, no. 9410, pp. 705–706, 2004.
- C Solis, A Martinez-Bermejo, T P Naidich, et al., “Acute intermittent porphyria: studies of the severe homozygous dominant disease provides insights into the neurologic attacks in acute porphyrias,” Archives of Neurology, vol. 61, no. 11, pp. 1764–1770, 2004.
- P Mustajoki, K Timonen, A Gorchein, A M Seppalainen, E Matikainen, and R Tenhunen, “Sustained high plasma 5-aminolaevulinic acid concentration in a volunteer: no porphyric symptoms,” European Journal of Clinical Investigation, vol. 22, no. 6, pp. 407–411, 1992.
- X Zhu, A K Raina, G Perry, and M A Smith, “Alzheimer's disease: the two-hit hypothesis,” Lancet Neurology, vol. 3, no. 4, pp. 219–226, 2004.
- L Zecca, M BH Youdim, P Riederer, J R Connor, and R R Crichton, “Iron, brain ageing and neurodegenerative disorders,” Nature Reviews. Neuroscience, vol. 5, no. 11, pp. 863–873, 2004.
- J R Jr Paterniti, C IP Lin, and D S Beattie, “-Aminolevulinic acid synthetase: regulation of activity in various tissues of the aging rat,” Archives of Biochemistry and Biophysics, vol. 191, no. 2, pp. 792–797, 1978.
- R J Castellani, P LR Harris, L M Sayre, et al., “Active glycation in neurofibrillary pathology of Alzheimer disease: -(carboxymethyl) lysine and hexitol-lysine,” Free Radical Biology and Medicine, vol. 31, no. 2, pp. 175–180, 2001.
- F Caballero, E Gerez, A Batlle, and E Vazquez, “Preventive aspirin treatment of streptozotocin induced diabetes: blockage of oxidative status and revertion of heme enzymes inhibition,” Chemico-Biological Interactions, vol. 126, no. 3, pp. 215–225, 2000.
- R Castellani, K Hirai, G Aliev, et al., “Role of mitochondrial dysfunction in Alzheimer's disease,” Journal of Neuroscience Research, vol. 70, no. 3, pp. 357–360, 2002.
- H Atamna, D W Killilea, A N Killilea, and B N Ames, “Heme deficiency may be a factor in the mitochondrial and neuronal decay of aging,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 23, pp. 14807–14812, 2002.
- H Atamna, J Liu, and B N Ames, “Heme deficiency selectively interrupts assembly of mitochondrial complex IV in human fibroblasts: relevance to aging,” Journal of Biological Chemistry, vol. 276, no. 51, pp. 48410–48416, 2001.
- B L Cussimanio, A A Booth, P Todd, B G Hudson, and R G Khalifah, “Unusual susceptibility of heme proteins to damage by glucose during non-enzymatic glycation,” Biophysical Chemistry, vol. 105, no. 2-3, pp. 743–755, 2003.
- M A Smith, R K Kutty, P L Richey, et al., “Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease,” American Journal of Pathology, vol. 145, no. 1, pp. 42–47, 1994.
- H M Schipper, S Cisse, and E G Stopa, “Expression of heme oxygenase-1 in the senescent and Alzheimer-diseased brain,” Annals of Neurology, vol. 37, no. 6, pp. 758–768, 1995.
- D Howlett, P Cutler, S Heales, and P Camilleri, “Hemin and related porphyrins inhibit -amyloid aggregation,” FEBS Letters, vol. 417, no. 2, pp. 249–251, 1997.
- B W Ahn, D U Song, Y D Jung, et al., “Detection of -amyloid peptide aggregation using DNA electrophoresis,” Analytical Biochemistry, vol. 284, no. 2, pp. 401–405, 2000.
- T Chernova, P Nicotera, and A G Smith, “Heme deficiency is associated with senescence and causes suppression of N-methyl-D-aspartate receptor subunits expression in primary cortical neurons,” Molecular Pharmacology, vol. 69, no. 3, pp. 697–705, 2006.
- A Sengupta, T Hon, and L Zhang, “Heme deficiency suppresses the expression of key neuronal genes and causes neuronal cell death,” Molecular Brain Research, vol. 137, no. 1-2, pp. 23–30, 2005.
- G Perry, A Nunomura, A D Cash, et al., “Reactive oxygen: its sources and significance in Alzheimer disease,” Journal of Neural Transmission, Supplement, no. 62, pp. 69–75, 2002.
- H P Monteiro, D SP Abdalla, A Faljoni-Alario, and E JH Bechara, “Generation of active oxygen species during coupled auto oxidation of oxyhemoglobin and -aminolevulinic acid,” Biochimica et Biophysica Acta, vol. 881, no. 1, pp. 100–106, 1986.
- T Douki, J Onuki, M HG Medeiros, E JH Bechara, J Cadet, and P Di Mascio, “DNA alkylation by 4,5-dioxovaleric acid, the final oxidation product of 5-aminolevulinic acid,” Chemical Research in Toxicology, vol. 11, no. 2, pp. 150–157, 1998.
- P Di Mascio, P C Teixeira, J Onuki, et al., “DNA damage by 5-aminolevulinic and 4,5-dioxovaleric acids in the presence of ferritin,” Archives of Biochemistry and Biophysics, vol. 373, no. 2, pp. 368–374, 2000.
- J Onuki, Y Chen, P C Teixeira, et al., “Mitochondrial and nuclear DNA damage induced by 5-aminolevulinic acid,” Archives of Biochemistry and Biophysics, vol. 432, no. 2, pp. 178–187, 2004.
- P I Oteiza, C G Kleinman, M Demasi, and E JH Bechara, “5-Aminolevulinic acid induces iron release from ferritin,” Archives of Biochemistry and Biophysics, vol. 316, no. 1, pp. 607–611, 1995.
- M EM Rocha, A MDC Ferreira, and E JH Bechara, “Roles of phosphate and an enoyl radical in ferritin iron mobilization by 5-aminolevulinic acid,” Free Radical Biology and Medicine, vol. 29, no. 12, pp. 1272–1279, 2000.
- M EM Rocha, F Dutra, B Bandy, et al., “Oxidative damage to ferritin by 5-aminolevulinic acid,” Archives of Biochemistry and Biophysics, vol. 409, no. 2, pp. 349–356, 2003.
- P Mustajoki, R Kauppinen, L Lannfelt, L Lilius, and J Koistinen, “Frequency of low erythrocyte porphobilinogen deaminase activity in Finland,” Journal of Internal Medicine, vol. 231, no. 4, pp. 389–395, 1992.
- Y Nordmann, H Puy, V Da Silva, et al., “Acute intermittent porphyria: prevalence of mutations in the porphobilinogen deaminase gene in blood donors in France,” Journal of Internal Medicine, vol. 242, no. 3, pp. 213–217, 1997.
- M I Kamboh, “Molecular genetics of late-onset Alzheimer's disease,” Annals of Human Genetics, vol. 68, no. 4, pp. 381–404, 2004.